Breast Cancer
Conference Coverage
T-DXd Moves Toward First Line for HER2-Low Metastatic BC
New results from DESTINY trials support use of the antibody-drug conjugate earlier in the treatment algorithm for cancers expressing even the...
Conference Coverage
Anti-Müllerian Hormone Predicts Chemo Benefits in BC
Hormone level measures may help some patients with HR+/HER2- invasive breast cancer avoid chemotherapy.
Feature
Should ER-Low Breast Cancer Patients Be Offered Endocrine Therapy?
New evidence suggests that omitting endocrine therapy increases the risk of death in this patient group.
Conference Coverage
Abemaciclib Plus Fulvestrant Improves Survival in Advanced Breast Cancer
A switch to a different CDK therapy addressed an unmet need for HR positive, HER2 negative advance breast cancer patients.
Latest News
Bariatric Surgery May Reduce Breast Cancer Risk for Some
“The surgical treatment benefit was predominantly seen in women with hyperinsulinemia, suggesting insulin may be used as a predictor of treatment...
Conference Coverage
Carefully Designing De-escalation Trials in Breast Cancer
Doctors highlight several strategies for designing de-escalation trials.
Feature
ADCs for Breast Cancer: Clear Benefits, Manageable Risks
The latest data on several ADCs — their clinical benefit and safety — were the focus of three presentations at the ESMO Breast Cancer Annual...
Feature
The ASCO Annual Meeting Starts This Week
More than 7000 abstracts were submitted for this year’s meeting a new record — and over 5000 were selected for presentation.
Latest News
Exercise Improves Sexual Health in Women With Metastatic Breast Cancer
Physical activity improved sexual health, fatigue, and quality of life.
From the Journals
ASTRO Releases New EBRT Guideline for Symptomatic Bone Mets
Recommendations concerning pain management and quality of life are part of the guidance.
From the Journals
ASCO Provides Guidance on CDK4/6 Inhibitors for Early Breast Cancer
A guideline update incorporates new high-quality evidence for the adjuvant use of CDK4/6 inhibitors in early breast cancer.